Clinical trial
A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Safety and Efficacy of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents (SLIMMER-YOUNG)
NCT07836270 is registered in ClinicalTrials.gov with Hangzhou Sciwind Biosciences Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Safety and Efficacy of Ecnoglutide Injection in Overweight or Obese Chinese Adolescents (SLIMMER-YOUNG)
- Lead sponsor
- Hangzhou Sciwind Biosciences Co., Ltd.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- October 31, 2026
- Completion date
- September 30, 2028
- Enrollment
- 192 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
adolescents with obesity, adolescents with overweight & weight-related comorbidities